Matt Cabrey joined Shire Pharmaceuticals four years ago as the corporate communications director when the British biopharma company had just began US expansion.

Shire now has a presence in 23 countries and is considered a leader in treatments for attention deficit and hyperactivity disorder (ADHD), gastrointestinal, and human genetic therapies. Its ADHD portfolio includes Adderall XR and Vyvanse.

When Cabrey joined the specialty pharma company, the role of the corporate communications arm was less focused on its ...